PB Ratio: 5.34
Is the P/B ratio high or low?
The P/B ratio of 5.34 is 22% below its 5-year average of 6.85, near the low end of its 5-year range (3.26–14.12).
19.01% above its 12-month average of 4.49.
TECH PB Ratio Chart
TECH Average PB Ratio Chart
TECH Current vs Average PB Ratio Chart
TECH PB Ratio Metrics
PB RATIO
5.34
PB RATIO AVG TTM
4.49
PB RATIO AVG 3Y
5.21
PB RATIO AVG 5Y
6.29
PB RATIO AVG 10Y
6.25
PB RATIO AVG 15Y
5.47
PB RATIO AVG 20Y
5.34
CURRENT VS TTM AVG
+19.01%
CURRENT VS 3Y AVG
+2.48%
CURRENT VS 5Y AVG
-15.11%
CURRENT VS 10Y AVG
-14.49%
CURRENT VS 15Y AVG
-2.43%
CURRENT VS 20Y AVG
+0.09%
TECH Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 5.34 | 4.49 | 5.21 | 6.29 |
| Insulet Corp. (PODD)vs › | $10.96B | 8.53 | 13.23 | 17.61 | 26.49 |
| Baxter International Inc. (BAX)vs › | $11.38B | 1.88 | 1.58 | 2.22 | 3.01 |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 2.70 | 2.16 | 3.72 | 4.80 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 1.44 | 1.00 | 0.99 | 1.29 |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | 3.54 | 2.66 | 2.83 | 3.98 |
| Tempus AI, Inc. (TEM)vs › | $9.80B | 24.13 | 28.39 | 68.48 | 68.48 |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 3.02 | 2.64 | 2.64 | 2.84 |
| Revvity, Inc. (RVTY)vs › | $12.61B | 1.76 | 1.50 | 1.65 | 2.12 |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 3.03 | 2.96 | 4.36 | 6.22 |
P/B vs. its own history
At 5.34, P/B is in its normal range, sitting higher than 52% of its 20-year history.
20-year low
3.26
median
5.23
20-year high
14.12
Book Value Analysis
P/B Ratio
5.34
Market Price / Book Value per Share
PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
PB Ratio FAQ
- What is the P/B ratio for Bio-Techne Corporation (TECH)?
- The P/B ratio for TECH stock is 5.34.
- Is Bio-Techne Corporation's P/B ratio high or low?
- The P/B ratio of 5.34 is 22% below its 5-year average of 6.85, near the low end of its 5-year range (3.26–14.12).
- What is the TTM average P/B ratio for Bio-Techne Corporation (TECH)?
- The TTM average P/B ratio for TECH stock is 4.49.
- What is the 3Y average P/B ratio for Bio-Techne Corporation (TECH)?
- The 3Y average P/B ratio for TECH stock is 5.21.
- What is the 5Y average P/B ratio for Bio-Techne Corporation (TECH)?
- The 5Y average P/B ratio for TECH stock is 6.29.
- What is the 10Y average P/B ratio for Bio-Techne Corporation (TECH)?
- The 10Y average P/B ratio for TECH stock is 6.25.
- What is the 15Y average P/B ratio for Bio-Techne Corporation (TECH)?
- The 15Y average P/B ratio for TECH stock is 5.47.
- What is the 20Y average P/B ratio for Bio-Techne Corporation (TECH)?
- The 20Y average P/B ratio for TECH stock is 5.34.
TECH PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-26 | 5.34 |
| 2026-06-25 | 5.32 |
| 2026-06-24 | 4.43 |
| 2026-06-23 | 4.23 |
| 2026-06-22 | 4.19 |
| 2026-06-18 | 4.36 |
| 2026-06-17 | 4.14 |
| 2026-06-16 | 4.22 |
| 2026-06-15 | 4.23 |
| 2026-06-12 | 4.06 |
| 2026-06-11 | 4.07 |
| 2026-06-10 | 3.95 |
| 2026-06-09 | 4.09 |
| 2026-06-08 | 3.96 |
| 2026-06-05 | 3.91 |
| 2026-06-04 | 4.00 |
| 2026-06-03 | 3.83 |
| 2026-06-02 | 3.75 |
| 2026-06-01 | 3.82 |
| 2026-05-29 | 3.89 |
| 2026-05-28 | 3.83 |
| 2026-05-27 | 3.62 |
| 2026-05-26 | 3.61 |
| 2026-05-22 | 3.63 |
| 2026-05-21 | 3.57 |
| 2026-05-20 | 3.51 |
| 2026-05-19 | 3.42 |
| 2026-05-18 | 3.34 |
| 2026-05-15 | 3.26 |
| 2026-05-14 | 3.37 |
| 2026-05-13 | 3.38 |
| 2026-05-12 | 3.57 |
| 2026-05-11 | 3.57 |
| 2026-05-08 | 3.64 |
| 2026-05-07 | 3.83 |
| 2026-05-06 | 3.57 |
| 2026-05-05 | 4.43 |
| 2026-05-04 | 4.27 |
| 2026-05-01 | 4.30 |
| 2026-04-30 | 4.32 |
| 2026-04-29 | 4.06 |
| 2026-04-28 | 4.18 |
| 2026-04-27 | 4.30 |
| 2026-04-24 | 4.23 |
| 2026-04-23 | 4.08 |
| 2026-04-22 | 4.57 |
| 2026-04-21 | 4.66 |
| 2026-04-20 | 4.73 |
| 2026-04-17 | 4.62 |
| 2026-04-16 | 4.48 |
| 2026-04-15 | 4.57 |
| 2026-04-14 | 4.58 |
| 2026-04-13 | 4.49 |
| 2026-04-10 | 4.34 |
| 2026-04-09 | 4.34 |
| 2026-04-08 | 4.31 |
| 2026-04-07 | 4.20 |
| 2026-04-06 | 4.20 |
| 2026-04-02 | 4.15 |
| 2026-04-01 | 4.18 |
| 2026-03-31 | 4.08 |
| 2026-03-30 | 4.06 |
| 2026-03-27 | 3.98 |
| 2026-03-26 | 4.11 |
| 2026-03-25 | 4.11 |
| 2026-03-24 | 4.09 |
| 2026-03-23 | 4.06 |
| 2026-03-20 | 4.02 |
| 2026-03-19 | 4.03 |
| 2026-03-18 | 3.97 |
| 2026-03-17 | 3.99 |
| 2026-03-16 | 3.81 |
| 2026-03-13 | 3.97 |
| 2026-03-12 | 4.02 |
| 2026-03-11 | 4.19 |
| 2026-03-10 | 4.12 |
| 2026-03-09 | 4.28 |
| 2026-03-06 | 4.21 |
| 2026-03-05 | 4.36 |
| 2026-03-04 | 4.52 |
| 2026-03-03 | 4.45 |
| 2026-03-02 | 4.51 |
| 2026-02-27 | 4.61 |
| 2026-02-26 | 4.52 |
| 2026-02-25 | 4.52 |
| 2026-02-24 | 4.50 |
| 2026-02-23 | 4.28 |
| 2026-02-20 | 4.49 |
| 2026-02-19 | 4.55 |
| 2026-02-18 | 4.63 |
| 2026-02-17 | 4.57 |
| 2026-02-13 | 4.68 |
| 2026-02-12 | 4.65 |
| 2026-02-11 | 4.95 |
| 2026-02-10 | 5.06 |
| 2026-02-09 | 5.11 |
| 2026-02-06 | 5.21 |
| 2026-02-05 | 5.14 |
| 2026-02-04 | 5.36 |
| 2026-02-03 | 5.14 |
| 2026-02-02 | 5.19 |
| 2026-01-30 | 5.10 |
| 2026-01-29 | 5.09 |
| 2026-01-28 | 5.21 |
| 2026-01-27 | 5.43 |
| 2026-01-26 | 5.38 |
| 2026-01-23 | 5.42 |
| 2026-01-22 | 5.54 |
| 2026-01-21 | 5.68 |
| 2026-01-20 | 5.53 |
| 2026-01-16 | 5.46 |
| 2026-01-15 | 5.56 |
| 2026-01-14 | 5.44 |
| 2026-01-13 | 5.28 |
| 2026-01-12 | 5.29 |
| 2026-01-09 | 5.23 |
| 2026-01-08 | 5.14 |
| 2026-01-07 | 5.17 |
| 2026-01-06 | 5.19 |
| 2026-01-05 | 5.01 |
| 2026-01-02 | 4.74 |
| 2025-12-31 | 4.68 |
| 2025-12-30 | 4.70 |
| 2025-12-29 | 4.71 |
| 2025-12-26 | 4.71 |
| 2025-12-24 | 4.71 |
| 2025-12-23 | 4.71 |
| 2025-12-22 | 4.69 |
| 2025-12-19 | 4.63 |
| 2025-12-18 | 4.54 |
| 2025-12-17 | 4.53 |
| 2025-12-16 | 4.57 |
| 2025-12-15 | 4.67 |
| 2025-12-12 | 4.65 |
| 2025-12-11 | 4.79 |
| 2025-12-10 | 4.84 |
| 2025-12-09 | 4.68 |
| 2025-12-08 | 4.80 |
| 2025-12-05 | 4.91 |
| 2025-12-04 | 5.05 |
| 2025-12-03 | 5.08 |
| 2025-12-02 | 5.01 |
| 2025-12-01 | 5.07 |
| 2025-11-28 | 5.13 |
| 2025-11-26 | 5.14 |
| 2025-11-25 | 5.24 |
| 2025-11-24 | 5.05 |
| 2025-11-21 | 4.89 |
| 2025-11-20 | 4.67 |
| 2025-11-19 | 4.60 |
| 2025-11-18 | 4.63 |
| 2025-11-17 | 4.66 |
| 2025-11-14 | 4.72 |
| 2025-11-13 | 4.83 |
| 2025-11-12 | 4.88 |
| 2025-11-11 | 4.71 |
| 2025-11-10 | 4.57 |
| 2025-11-07 | 4.57 |
| 2025-11-06 | 4.63 |
| 2025-11-05 | 4.77 |
| 2025-11-04 | 4.96 |
| 2025-11-03 | 4.97 |
| 2025-10-31 | 5.08 |
| 2025-10-30 | 4.95 |
| 2025-10-29 | 5.03 |
| 2025-10-28 | 5.19 |
| 2025-10-27 | 5.22 |
| 2025-10-24 | 5.35 |
| 2025-10-23 | 5.36 |
| 2025-10-22 | 5.18 |
| 2025-10-21 | 5.15 |
| 2025-10-20 | 5.08 |
| 2025-10-17 | 5.02 |
| 2025-10-16 | 5.00 |
| 2025-10-15 | 4.84 |
| 2025-10-14 | 4.81 |
| 2025-10-13 | 4.84 |
| 2025-10-10 | 4.76 |
| 2025-10-09 | 4.86 |
| 2025-10-08 | 4.92 |
| 2025-10-07 | 4.80 |
| 2025-10-06 | 5.03 |
| 2025-10-03 | 5.11 |
| 2025-10-02 | 5.04 |
| 2025-10-01 | 4.86 |
| 2025-09-30 | 4.52 |
| 2025-09-29 | 4.24 |
| 2025-09-26 | 4.21 |
| 2025-09-25 | 4.10 |
| 2025-09-24 | 4.16 |
| 2025-09-23 | 4.30 |
| 2025-09-22 | 4.31 |
| 2025-09-19 | 4.31 |
| 2025-09-18 | 4.30 |
| 2025-09-17 | 4.18 |
| 2025-09-16 | 4.20 |
| 2025-09-15 | 4.19 |
| 2025-09-12 | 4.16 |
| 2025-09-11 | 4.32 |
| 2025-09-10 | 4.14 |
| 2025-09-09 | 4.40 |
| 2025-09-08 | 4.39 |
| 2025-09-05 | 4.42 |
| 2025-09-04 | 4.30 |
| 2025-09-03 | 4.33 |
| 2025-09-02 | 4.34 |
| 2025-08-29 | 4.43 |
| 2025-08-28 | 4.41 |
| 2025-08-27 | 4.56 |
| 2025-08-26 | 4.61 |
| 2025-08-25 | 4.60 |
| 2025-08-22 | 4.63 |
| 2025-08-21 | 4.25 |
| 2025-08-20 | 4.28 |
| 2025-08-19 | 4.32 |
| 2025-08-18 | 4.20 |
| 2025-08-15 | 4.22 |
| 2025-08-14 | 4.23 |
| 2025-08-13 | 4.31 |
| 2025-08-12 | 4.16 |
| 2025-08-11 | 3.95 |
| 2025-08-08 | 3.97 |
| 2025-08-07 | 3.95 |
| 2025-08-06 | 3.93 |
| 2025-08-05 | 4.30 |
| 2025-08-04 | 4.32 |
| 2025-08-01 | 4.32 |
| 2025-07-31 | 4.31 |
| 2025-07-30 | 4.55 |
| 2025-07-29 | 4.56 |
| 2025-07-28 | 4.61 |
| 2025-07-25 | 4.63 |
| 2025-07-24 | 4.61 |
| 2025-07-23 | 4.36 |
| 2025-07-22 | 4.18 |
| 2025-07-21 | 3.96 |
| 2025-07-18 | 4.10 |
| 2025-07-17 | 4.20 |
| 2025-07-16 | 4.08 |
| 2025-07-15 | 4.05 |
| 2025-07-14 | 4.14 |
| 2025-07-11 | 4.26 |
| 2025-07-10 | 4.29 |
| 2025-07-09 | 4.14 |
| 2025-07-08 | 4.15 |
| 2025-07-07 | 4.06 |
| 2025-07-03 | 4.19 |
| 2025-07-02 | 4.19 |
| 2025-07-01 | 4.10 |
| 2025-06-30 | 4.05 |
| 2025-06-27 | 4.08 |
| 2025-06-26 | 4.16 |
| 2025-06-25 | 4.09 |
| 2025-06-24 | 3.94 |
| 2025-06-23 | 3.88 |
| 2025-06-20 | 3.93 |
| 2025-06-18 | 3.95 |
| 2025-06-17 | 3.90 |
| 2025-06-16 | 4.07 |
| 2025-06-13 | 3.98 |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman